Intranasal lidocaine to block the sphenopalatine ganglion in refractory chronic migraines: a case report
Bazan, Marlon. 2018. Intranasal lidocaine to block the sphenopalatine ganglion in refractory chronic migraines: a case report -- In Proceedings: 14th Annual Symposium on Graduate Research and Scholarly Projects. Wichita, KS: Wichita State University, p. 13
Intranasal lidocaine to treat chronic migraines may be a viable option after first and second line treatments are exhausted. It is thought to work by blocking the sphenopalatine ganglion. Although data from randomized placebo-controlled trials are inconsistent, intranasal lidocaine is rapid, safe, and easily implemented in an outpatient setting. This is a case report of a 58-year-old female who initially presented with migraines and associated phonophobia and photophobia who failed multiple treatment options including topiramate, propranolol, ketorolac, promethazine, nortriptyline, botulinum toxin injections, daith piercing, lamotrigine, and narcotics. She responded favorably to lidocaine 4% intra-nasally. She continued receiving this treatment for more than 12 months before it ultimately diminished in efficacy.
Presented to the 14th Annual Symposium on Graduate Research and Scholarly Projects (GRASP) held at the Rhatigan Student Center, Wichita State University, April 27, 2018.
Research completed in the Department of Physician Assistant, College of Health Professions